All In Biotech

BLA 761121 · Genentech

Polivy

Polatuzumab Vedotin-Piiq · Intravenous

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jun 10, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

107

10 Phase 3, 37 recruiting

FAERS reports

10,202

9,659 serious, 2,154 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 24, 2026.

POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. ( 1.1 ) in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies. ( 1.2 ) 1.1 Previously Untreated DLBCL, NOS or HGBL POLIVY in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. 1.2 Relapsed or Refractory DLBCL, NOS POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.

Mechanism: Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecule, MMAE, is an anti-mitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, a B-cell specific surface protein, which is a component of the B-cell receptor. Upon binding CD79b, polatuzumab vedotin-piiq is internalized, and the linker is cleaved by lysosomal proteases to enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 19, 2023 Supplement 8 · Efficacy OrphanLabelLetterReview
  • Jun 10, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelReviewLetter
2 products under this application
  • POLIVY · POLATUZUMAB VEDOTIN-PIIQ 140MG/VIAL · POWDER, INTRAVENOUS · Prescription
  • POLIVY · POLATUZUMAB VEDOTIN-PIIQ 30MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Polatuzumab Vedotin" as an intervention, any sponsor and status, largest first.

All 107 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression2,064
  • off label use1,398
  • death801
  • neutropenia642
  • anaemia577
  • covid-19549
  • febrile neutropenia549
  • cytokine release syndrome542
  • pyrexia531
  • drug ineffective503
  • platelet count decreased434
  • diffuse large b-cell lymphoma428

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20142
20158
201635
201721
201832
2019253
2020467
2021719
20221,665
20232,266
20241,733
20251,550
20261,449

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Polivy (Polatuzumab Vedotin-Piiq)

2024 spending

$3.8M

Beneficiaries

54

200 claims

Per beneficiary

$70,156

$12,602.91 per unit

View as table
YearSpending
2020$388,010
2021$327,833
2022$958,382
2023$1,291,224
2024$3,788,412

Part B: Polivy (Polatuzumab Vedotin-Piiq) · HCPCS J9309

2024 spending

$202M

Beneficiaries

3,042

10,844 claims

Per beneficiary

$66,241

2024 ASP limit $127.02 per unit

View as table
YearSpending
2020$48,096,602
2021$42,318,868
2022$66,197,899
2023$118,943,447
2024$201,503,836

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 54 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.